We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Centene Q3 Earnings Call Highlights Faster Recovery and Medicaid Risks
Read MoreHide Full Article
Key Takeaways
Centene's Q3 adjusted EPS of 58 cents beat the 7-cent estimate, lifting its 2026 guidance floor above $5.20.
Medicare Advantage is set to break even a year early, while Part D margins could moderate to 2%-3% in 2027.
Medicaid enrollment may fall 8%-9% by year-end, while Marketplace margins are expected to reach 5% in 2026.
Centene Corporation (CNC - Free Report) raised its 2026 earnings outlook after a stronger-than-expected third quarter, with Medicare outperforming and Medicaid and Marketplace tracking to plan. Management also outlined a path to further earnings growth in 2027.
The call centered on whether improving medical costs and pricing can offset Medicaid enrollment losses and a reset in Medicare prescription drug margins.
CNC Raises Its 2026 Outlook
Chief financial officer Andrew Asher increased the full-year adjusted earnings guidance floor to greater than $5.20 per share from greater than $4.80, citing Medicare strength, Marketplace margin improvement and lower interest expense.
Centene’s third-quarter adjusted earnings of 58 cents per share beat the Zacks Consensus Estimate of 7 cents. Total revenues of $50.65 billion also topped the $47.06 billion consensus.
Asher expects 2027 adjusted earnings to exceed both the updated 2026 guidance and an approximately $4.70 baseline that removes 50 cents of earnings not expected to recur.
Centene Faces Medicaid Enrollment Pressure
CEO Sarah London said Medicaid's 93.6% health benefits ratio improved 30 basis points sequentially, reflecting rate actions and medical cost initiatives. Behavioral health and home health trends showed further stabilization.
Medicaid membership ended September at 11.9 million. Management still expects year-end membership to decline 8% to 9% from December 2025 as eligibility changes and program transitions take effect.
During the Q&A, a Bank of America analyst pressed on 2027 acuity risks. London emphasized the danger of reimbursement rates falling behind members' medical needs while noting that states are discussing prospective adjustments tied to work requirements.
CNC Sees Medicare Recovery Ahead of Schedule
London said Medicare Advantage is on track to break even in 2026, one year earlier than planned, helped by favorable medical costs and disciplined execution.
Centene is narrowing its 2027 Medicare Advantage footprint toward markets and populations where its products can deliver greater value. Management expects membership to decline but margins to expand next year.
Asher attributed most Medicare outperformance to prescription drug plans. He lifted the 2026 Part D pretax margin forecast to the mid-to-high 3% range, but told a Wolfe Research analyst that initial 2027 margin expectations could reset to 2% to 3%.
Centene Targets Further Marketplace Margin Gains
London expects the Marketplace business to deliver a 2026 pretax margin at the top of its earlier 4.5% to 5% range, supported by moderating medical trends among higher-acuity silver-tier members.
Management absorbed reserve adjustments tied to independent dispute resolution claims and other program integrity measures during the quarter. Asher told a Wells Fargo analyst that the catch-up reserve expense was not expected to recur in the fourth quarter.
For 2027, London expects slight contraction in the broader exchange market. Centene has adjusted county-level pricing and expanded Ambetter offerings, prioritizing further margin improvement over a specific enrollment target.
CNC Focuses on Efficiency and Debt Reduction
Asher reported an adjusted selling, general and administrative expense ratio of 6.5%, down from 7% a year earlier. Management expects further efficiency gains in 2027.
Asked by a Barclays analyst about workforce optimization, Asher reaffirmed roughly $480 million of associated costs, largely excluded from adjusted results, but did not quantify annual savings.
Centene also repurchased additional senior notes, bringing debt to approximately $15 billion by the October call. Asher said reduced borrowings should lower interest costs and preserve capacity for future opportunities.
Centene Keeps 2027 Execution in Focus
London characterized the operating trajectory as improving but stressed continued coordination with states on Medicaid rate adequacy and enrollment transitions.
Asher said formal 2027 guidance will follow in February, when enrollment results and Medicaid rates provide greater visibility. The priorities remain margin recovery, cost control and disciplined portfolio management.
Its Value Score of A and Growth Score of A point to attractive characteristics in those styles, while its Momentum Score of B remains favorable. The combined VGM Score of A complements its Buy rank, although the Zacks Rank may change as analysts revise estimates following the reported results.
View the Zacks #1 Rank List
Image: Shutterstock
Centene Q3 Earnings Call Highlights Faster Recovery and Medicaid Risks
Key Takeaways
Centene Corporation (CNC - Free Report) raised its 2026 earnings outlook after a stronger-than-expected third quarter, with Medicare outperforming and Medicaid and Marketplace tracking to plan. Management also outlined a path to further earnings growth in 2027.
The call centered on whether improving medical costs and pricing can offset Medicaid enrollment losses and a reset in Medicare prescription drug margins.
CNC Raises Its 2026 Outlook
Chief financial officer Andrew Asher increased the full-year adjusted earnings guidance floor to greater than $5.20 per share from greater than $4.80, citing Medicare strength, Marketplace margin improvement and lower interest expense.
Centene’s third-quarter adjusted earnings of 58 cents per share beat the Zacks Consensus Estimate of 7 cents. Total revenues of $50.65 billion also topped the $47.06 billion consensus.
Asher expects 2027 adjusted earnings to exceed both the updated 2026 guidance and an approximately $4.70 baseline that removes 50 cents of earnings not expected to recur.
Centene Faces Medicaid Enrollment Pressure
CEO Sarah London said Medicaid's 93.6% health benefits ratio improved 30 basis points sequentially, reflecting rate actions and medical cost initiatives. Behavioral health and home health trends showed further stabilization.
Medicaid membership ended September at 11.9 million. Management still expects year-end membership to decline 8% to 9% from December 2025 as eligibility changes and program transitions take effect.
During the Q&A, a Bank of America analyst pressed on 2027 acuity risks. London emphasized the danger of reimbursement rates falling behind members' medical needs while noting that states are discussing prospective adjustments tied to work requirements.
CNC Sees Medicare Recovery Ahead of Schedule
London said Medicare Advantage is on track to break even in 2026, one year earlier than planned, helped by favorable medical costs and disciplined execution.
Centene is narrowing its 2027 Medicare Advantage footprint toward markets and populations where its products can deliver greater value. Management expects membership to decline but margins to expand next year.
Asher attributed most Medicare outperformance to prescription drug plans. He lifted the 2026 Part D pretax margin forecast to the mid-to-high 3% range, but told a Wolfe Research analyst that initial 2027 margin expectations could reset to 2% to 3%.
Centene Targets Further Marketplace Margin Gains
London expects the Marketplace business to deliver a 2026 pretax margin at the top of its earlier 4.5% to 5% range, supported by moderating medical trends among higher-acuity silver-tier members.
Management absorbed reserve adjustments tied to independent dispute resolution claims and other program integrity measures during the quarter. Asher told a Wells Fargo analyst that the catch-up reserve expense was not expected to recur in the fourth quarter.
For 2027, London expects slight contraction in the broader exchange market. Centene has adjusted county-level pricing and expanded Ambetter offerings, prioritizing further margin improvement over a specific enrollment target.
CNC Focuses on Efficiency and Debt Reduction
Asher reported an adjusted selling, general and administrative expense ratio of 6.5%, down from 7% a year earlier. Management expects further efficiency gains in 2027.
Asked by a Barclays analyst about workforce optimization, Asher reaffirmed roughly $480 million of associated costs, largely excluded from adjusted results, but did not quantify annual savings.
Centene also repurchased additional senior notes, bringing debt to approximately $15 billion by the October call. Asher said reduced borrowings should lower interest costs and preserve capacity for future opportunities.
Centene Keeps 2027 Execution in Focus
London characterized the operating trajectory as improving but stressed continued coordination with states on Medicaid rate adequacy and enrollment transitions.
Asher said formal 2027 guidance will follow in February, when enrollment results and Medicaid rates provide greater visibility. The priorities remain margin recovery, cost control and disciplined portfolio management.
CNC's Zacks Rank & Style Scores
CNC carries a Zacks Rank #2 (Buy) at present, indicating a favorable near-term earnings-estimate-revision profile under the Zacks methodology. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Its Value Score of A and Growth Score of A point to attractive characteristics in those styles, while its Momentum Score of B remains favorable. The combined VGM Score of A complements its Buy rank, although the Zacks Rank may change as analysts revise estimates following the reported results.